Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts

William D. Clouse, Hiroki Yamaguchi, Michael R. Phillips, Richard D. Hurt, Lorraine A. Fitzpatrick, Thomas P. Moyer, Charles Rowland, Hartzell V Schaff, Virginia M Miller

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Smoking is a major risk factor for failure of coronary artery bypass grafts (CABG). Experiments were designed to determine effects of transdermal nicotine, independent of smoking, on structure and function of CABG. Saphenous veins were placed as CABG in untreated dogs (control) or in dogs treated with transdermal nicotine (one 11-mg or two 22-mg patches/day) for 5 wk. Serum nicotine and plasma nitric oxide were measured. Grafts were removed and prepared for organ chamber studies and histology. Serum nicotine averaged 12.1 and 118.7 ng/ml in the 11 mg/day and 44 mg/day groups, respectively. Plasma nitric oxide was higher in dogs treated with 11 mg/day doses compared with controls. In organ chamber studies, endothelium-dependent relaxations to thrombin and A-23187 and endothelium-independent relaxations to nitric oxide were greatest in grafts from dogs treated with 11 mg/day doses. Intimal thickness of the grafts were similar among groups. However, staining for bone sialoprotein was increased in the media of grafts from the 11 mg/day treatment group. These data suggest that transdermal nicotine in doses comparable and double to those used for conventional smoking cessation treatment in humans does not adversely affect early patency of canine CABG up to 4 wk postoperatively. Transdermal nicotine, however, may increase production of and response to nitric oxide in bypass grafts.

Original languageEnglish (US)
Pages (from-to)1213-1223
Number of pages11
JournalJournal of Applied Physiology
Volume89
Issue number3
StatePublished - 2000

Fingerprint

Nicotine
Coronary Artery Bypass
Transplants
Nitric Oxide
Dogs
Therapeutics
Endothelium
Smoking
Integrin-Binding Sialoprotein
Tunica Intima
Withholding Treatment
Saphenous Vein
Calcimycin
Smoking Cessation
Serum
Thrombin
Canidae
Histology
Staining and Labeling

Keywords

  • Endothelium
  • Nitric oxide
  • Saphenous vein
  • Smoking cessation
  • Vascular smooth muscle

ASJC Scopus subject areas

  • Physiology
  • Endocrinology
  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Clouse, W. D., Yamaguchi, H., Phillips, M. R., Hurt, R. D., Fitzpatrick, L. A., Moyer, T. P., ... Miller, V. M. (2000). Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts. Journal of Applied Physiology, 89(3), 1213-1223.

Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts. / Clouse, William D.; Yamaguchi, Hiroki; Phillips, Michael R.; Hurt, Richard D.; Fitzpatrick, Lorraine A.; Moyer, Thomas P.; Rowland, Charles; Schaff, Hartzell V; Miller, Virginia M.

In: Journal of Applied Physiology, Vol. 89, No. 3, 2000, p. 1213-1223.

Research output: Contribution to journalArticle

Clouse, WD, Yamaguchi, H, Phillips, MR, Hurt, RD, Fitzpatrick, LA, Moyer, TP, Rowland, C, Schaff, HV & Miller, VM 2000, 'Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts', Journal of Applied Physiology, vol. 89, no. 3, pp. 1213-1223.
Clouse WD, Yamaguchi H, Phillips MR, Hurt RD, Fitzpatrick LA, Moyer TP et al. Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts. Journal of Applied Physiology. 2000;89(3):1213-1223.
Clouse, William D. ; Yamaguchi, Hiroki ; Phillips, Michael R. ; Hurt, Richard D. ; Fitzpatrick, Lorraine A. ; Moyer, Thomas P. ; Rowland, Charles ; Schaff, Hartzell V ; Miller, Virginia M. / Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts. In: Journal of Applied Physiology. 2000 ; Vol. 89, No. 3. pp. 1213-1223.
@article{35d35c0f0b87434f92724fb6544e6afc,
title = "Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts",
abstract = "Smoking is a major risk factor for failure of coronary artery bypass grafts (CABG). Experiments were designed to determine effects of transdermal nicotine, independent of smoking, on structure and function of CABG. Saphenous veins were placed as CABG in untreated dogs (control) or in dogs treated with transdermal nicotine (one 11-mg or two 22-mg patches/day) for 5 wk. Serum nicotine and plasma nitric oxide were measured. Grafts were removed and prepared for organ chamber studies and histology. Serum nicotine averaged 12.1 and 118.7 ng/ml in the 11 mg/day and 44 mg/day groups, respectively. Plasma nitric oxide was higher in dogs treated with 11 mg/day doses compared with controls. In organ chamber studies, endothelium-dependent relaxations to thrombin and A-23187 and endothelium-independent relaxations to nitric oxide were greatest in grafts from dogs treated with 11 mg/day doses. Intimal thickness of the grafts were similar among groups. However, staining for bone sialoprotein was increased in the media of grafts from the 11 mg/day treatment group. These data suggest that transdermal nicotine in doses comparable and double to those used for conventional smoking cessation treatment in humans does not adversely affect early patency of canine CABG up to 4 wk postoperatively. Transdermal nicotine, however, may increase production of and response to nitric oxide in bypass grafts.",
keywords = "Endothelium, Nitric oxide, Saphenous vein, Smoking cessation, Vascular smooth muscle",
author = "Clouse, {William D.} and Hiroki Yamaguchi and Phillips, {Michael R.} and Hurt, {Richard D.} and Fitzpatrick, {Lorraine A.} and Moyer, {Thomas P.} and Charles Rowland and Schaff, {Hartzell V} and Miller, {Virginia M}",
year = "2000",
language = "English (US)",
volume = "89",
pages = "1213--1223",
journal = "Journal of Applied Physiology",
issn = "8750-7587",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts

AU - Clouse, William D.

AU - Yamaguchi, Hiroki

AU - Phillips, Michael R.

AU - Hurt, Richard D.

AU - Fitzpatrick, Lorraine A.

AU - Moyer, Thomas P.

AU - Rowland, Charles

AU - Schaff, Hartzell V

AU - Miller, Virginia M

PY - 2000

Y1 - 2000

N2 - Smoking is a major risk factor for failure of coronary artery bypass grafts (CABG). Experiments were designed to determine effects of transdermal nicotine, independent of smoking, on structure and function of CABG. Saphenous veins were placed as CABG in untreated dogs (control) or in dogs treated with transdermal nicotine (one 11-mg or two 22-mg patches/day) for 5 wk. Serum nicotine and plasma nitric oxide were measured. Grafts were removed and prepared for organ chamber studies and histology. Serum nicotine averaged 12.1 and 118.7 ng/ml in the 11 mg/day and 44 mg/day groups, respectively. Plasma nitric oxide was higher in dogs treated with 11 mg/day doses compared with controls. In organ chamber studies, endothelium-dependent relaxations to thrombin and A-23187 and endothelium-independent relaxations to nitric oxide were greatest in grafts from dogs treated with 11 mg/day doses. Intimal thickness of the grafts were similar among groups. However, staining for bone sialoprotein was increased in the media of grafts from the 11 mg/day treatment group. These data suggest that transdermal nicotine in doses comparable and double to those used for conventional smoking cessation treatment in humans does not adversely affect early patency of canine CABG up to 4 wk postoperatively. Transdermal nicotine, however, may increase production of and response to nitric oxide in bypass grafts.

AB - Smoking is a major risk factor for failure of coronary artery bypass grafts (CABG). Experiments were designed to determine effects of transdermal nicotine, independent of smoking, on structure and function of CABG. Saphenous veins were placed as CABG in untreated dogs (control) or in dogs treated with transdermal nicotine (one 11-mg or two 22-mg patches/day) for 5 wk. Serum nicotine and plasma nitric oxide were measured. Grafts were removed and prepared for organ chamber studies and histology. Serum nicotine averaged 12.1 and 118.7 ng/ml in the 11 mg/day and 44 mg/day groups, respectively. Plasma nitric oxide was higher in dogs treated with 11 mg/day doses compared with controls. In organ chamber studies, endothelium-dependent relaxations to thrombin and A-23187 and endothelium-independent relaxations to nitric oxide were greatest in grafts from dogs treated with 11 mg/day doses. Intimal thickness of the grafts were similar among groups. However, staining for bone sialoprotein was increased in the media of grafts from the 11 mg/day treatment group. These data suggest that transdermal nicotine in doses comparable and double to those used for conventional smoking cessation treatment in humans does not adversely affect early patency of canine CABG up to 4 wk postoperatively. Transdermal nicotine, however, may increase production of and response to nitric oxide in bypass grafts.

KW - Endothelium

KW - Nitric oxide

KW - Saphenous vein

KW - Smoking cessation

KW - Vascular smooth muscle

UR - http://www.scopus.com/inward/record.url?scp=0034495767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034495767&partnerID=8YFLogxK

M3 - Article

C2 - 10956371

AN - SCOPUS:0034495767

VL - 89

SP - 1213

EP - 1223

JO - Journal of Applied Physiology

JF - Journal of Applied Physiology

SN - 8750-7587

IS - 3

ER -